U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

BCG, in use since 1921 and originally developed as a live vaccine against tuberculosis, also forms a key part of the non-muscle invasive bladder cancer (NMIBC) armamentarium. NMIBC accounts for ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent immunogenicity with CD8+ and CD4+ T cell stimulation and improved safety compared to earlier BCG ...

Academic researchers in Massachusetts believe the standard BCG (bacillus Calmette-Guérin) vaccine could have a remarkable second use: a treatment to reverse advanced type 1 diabetes. The cause of ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.

Long COVID sequelae are reduced at 6 and 12 months when the BCG vaccine is administered during acute COVID-19. If administered within the COVID-19 convalescence period, the intradermal Bacillus ...

The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...

New York-based Panther Life Sciences Corp. announced a partnership with Pitt BioForge to advance Panther's Microarray Patch ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

The Space Needle is a 605-foot observation tower that defines the skyline of Seattle and serves as a symbol of the city. “It’s really an icon,” says Rick Chesmore, a cofounder of Chesmore ...